Constipation
Conditions
Keywords
Colonic transit, Dietary Fiber, Radiopaque marker
Brief summary
The purpose of this study is to assess the efficacy of resistant maltodextrins, compared to placebo, in reducing the colonic transit time in healthy subjects.
Detailed description
In the last fifty years we have drastically changed our eating habits, in particular our fibre intake. Our hunter-gatherer ancestors ate more than 100 species of fruit and vegetables, which contributed between 20 and 30 g of dietary fibre per day. Currently, a typical citizen of our country reaches 10% of that amount. Therefore, fibre deficiency alters digestion and metabolism, increasing nutrient absorption (obesity, increased insulin resistance, hyperlipidaemias), produces altered colonic metabolism (inflammatory bowel disease), and slows faecal transit (increasing the lumen pressure with diverticulosis, appendicitis, haemorrhoids and colon cancer. In addition, the prebiotic effect is important. Several studies have demonstrated the effectiveness of digestion-resistant maltodextrin in the treatment of chronic idiopathic constipation. Investigators carried out a single blind study among young people with constipation who were administered 9.2 grams of resistant maltodextrins per day or placebo, and found significant changes in defecation frequency and in faecal volume. Kimura et al. carried out a clinical trial in women with constipation and a defecation frequency of less than 3 times per week and administered 5 grams of resistant maltodextrins per day, demonstrating its effectiveness in significantly increasing the number of defecations per week, the number of days per week without defecation and the faecal volume. Additionally, an improvement was found aspects such as colour, stool odour and psychological feeling after defecation. Finally, an interesting feature of Resistant maltodextrins is that it normalises the colonic transit time without causing diarrhoea, whilst increasing the stool volume, moisture and frequency of defecation. The purpose of this study is to assess the efficacy of resistant maltodextrins, compared to placebo, in reducing the colonic transit time in healthy subjects. For That, 60 subjects will be stratified by gender (30 women: 15 with resistant maltodextrins and 15 placebo and 30 men: 15 with resistant maltodextrins and 15 placebo).
Interventions
DIETARY_SUPPLEMENTResistant maltodextrins
15 grams of Resistant maltodextrins per day dissolved in water during 21 days
OTHERplacebo
15gr placebo
Sponsors
Universidad Católica San Antonio de Murcia
Hospital Virgen de la Vega
San Antonio Technologies - San Antonio Catholic University of Murcia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects of both sexes (men and women) between 18 and 30 years old of Caucasian race selected from the general population * Subjects capable of understanding the clinical study, willing to provide written informed consent and to fulfil the procedures and requirements of the study.
Exclusion criteria
* Diagnosis of a BMI ≥ 30 Kg/m2. * Individuals with a daily defecation habit. * Subjects with a history of any digestive disease or who have undergone gastrointestinal surgery (excluding appendicectomy or herniorrhaphy), abdominal surgery in the last two years or any recent major extra-abdominal surgery. * Subjects with diabetes, hypothyroidism or hyperthyroidism. * Subjects with a history of systemic disease that might effect gut motility. * Subjects on dietary treatment and/or drugs that effect body weight or appetite. * Individuals that have had any change in dietary habit in the last 2 months. * Subjects with a history of drug or alcohol abuse, or other substances or factors that might limit their ability to cooperate during the study. * Subjects with bowel habits affected by stress. * Subjects taking medication or drugs that alter gut motility. * Pregnant women. * Subjects that have stopped smoking in the last 6 months or who intend to give up smoking during the study. * Subjects with allergies or eating disorders. * Subjects that consume an excessive amount of alcohol (\>3 glasses of wine or beer per day) * Individuals that engage in physical exercise two or more times per week. * Subjects whose condition makes them ineligible to take part in the study, according to the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Colonic Transit Time (CTT) | 28 days from the start of the study | to determine CTT volunteers should ingest a capsule of radiopaque markers each day for five consecutive days. 24 hours after the final intake of markers an abdominal X-ray should be performed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Segmental colonic transit time (SCTT) | 28 days from the start of the study | to determine CTT volunteers should ingest a capsule of radiopaque markers each day for five consecutive days. 24 hours after the final intake of markers an abdominal X-ray should be performed. |
| Defecation frequency (DF) | 28 days | — |
| Stool Consistency | 28 days | Each of the study subjects will be given a defecation habit diary where consistency of stools from the 28 days of the experimental phase will be recorded according to the Bristol Stool Chart |
| Stool volume by just their eye observation | 28 days | — |
| Assessment of dietary fibre intake | from day 2 to day 6 and from day 23 to day 27 | This outcome will be assessed using a dietary survey. A five-day food record. This food record will be carried out at the same days in both study phases (from day 2 to day 6 and from day 23 to day 27). This data will be processed by a computer system that uses internationally validated food composition tables |
| Efficacy Blood analysis | 28 days | A blood sample will be taken to determine the blood count and blood biochemistry (glucose, lipid profile, ferritin and ions). |
| Safety Blood analysis | 29 days | An analysis of blood biochemistry will be carried out to determine values for enzymes to assess liver function, and biomolecules such as bilirubin, urea and creatinine to assess renal function |
| Clinical Variables of Intestinal Function | 28 days | these variables will be assessed by determining the number of the Rome III Criteria they fulfil |
Other
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 29 days | The safety profile will be assessed using the record of adverse events. Adverse events related to this study will be due to the intake of soluble fibre, the most frequently reported being: flatulence, diarrhoea and gastrointestinal bloating. |
Countries
Spain
Outcome results
None listed